Anti-Cortactin Antibody, clone 1F15 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1F15 is a Rabbit recombinant monoclonal antibody that specifically detects Cortactin. It targets an epitope within 20 amino acids from the C-terminal half.

KLH-conjugated linear peptide corresponding to 20 amino acids from the C-terminal half of human Cortactin.

Quality Control Testing

Evaluated by Western Blotting in K562 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Cortactin in K562 cell lysate.

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Cortactin in HeLa, NIH3T3, and L6 cell lysates.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Cortactin in A431, HeLa, HepG2 and NIH 3T3 cells.

Affinity Binding Assay: A representative lot of this antibody bound Cortactin with a KD of 2.7 x 10-7 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Cortactin in human stomach tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-Cortactin, clone 1F15 ZooMAb^®, Cat. No. ZRB1329, is a recombinant Rabbit monoclonal antibody that targets Cortactin and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Src substrate cortactin (UniProt: Q14247; also known as Amplaxin, Oncogene EMS1) is encoded by the CTTN (also known as EMS) gene (Gene ID: 2017) in human. Cortactin is a peripheral membrane protein that serves as a substrate for Src tyrosine kinase and plays a role in regulating cell motility. It is shown to interact with F-actin to promote its polymerization and branching and contributes to the organization of the actin cytoskeleton and cell shape. It also plays a role in the formation of lamellipodia and in cell migration. Cortactin contains an N-terminal acidic domain, six and a half tandem repeats of a unique 37-amino acid sequence, and a C-terminal Src homology (SH3) domain (aa 492-550). The repeat regions are shown to be essential for F-actin binding. Cortactin is activated via phosphorylation by upstream kinases in response to extracellular stimuli. In mice, Src kinase primarily phosphorylates cortactin at tyrosines 421, 466, and 482, which leads its interaction with F-actin and Arp2/3. It can also be phosphorylated by ERK on serine 405 and 418 that results in recruitment of additional actin nucleation-promoting factors (NPFs), most importantly N-WASP, to the Arp2/3/ complex. Cortactin can undergo acetylation by p300 and PCAF acetyltransferase and its acetylation sites are shown to cluster in the repeat region of cortactin harboring its F-actin binding site. Acetylated cortactin loses the positive charge at respective lysines that results in the loss of its F-actin binding. Overexpression of cortactin has been reported in many human tumors and its expression correlates well with the metastatic potential of breast cancer cells and hepatocellular carcinomas. Its level is associated with increased cell migration, metastasis, and poor prognosis. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Gattazzo, C. (2014). Haematologica. 99(6); 1069-1077).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb^® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

30 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.